At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 784 enrolled
Drug / intervention
Pimavanserin +1 moredrug
Likely dose
Pimavanserin 34 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease
In Brief
A Phase 3 clinical trial evaluating Pimavanserin and Placebo for Neuropsychiatric Symptoms Related to Neurodegenerative Disease. Completed, enrolled 784 participants across 104 sites in 12 countries.
Detailed Summary
The purpose of this study is to assess the safety and tolerability of pimavanserin compared to placebo in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBulgaria, Colombia, Czechia, Georgia, Mexico, Poland, Romania, Russia, Serbia, South Africa, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartMay 2018
First PostedJul 2018
Primary CompletionMay 2022
TodayJul 2026
First PostedJul 2, 2018
Enrollment StartMay 21, 2018
Primary CompletionMay 6, 2022
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 8 years ago
Interventions
Pimavanserindrug
Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets)
Placebodrug
Placebo, tablets, once daily by mouth (provided as two placebo tablets)